WHG
ABCL icon

Westwood Holdings Group’s AbCellera Biologics ABCL Stock Holding History

Westwood Holdings Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,408
Closed -$116K – 483
2023
Q1 		$116K Buy
+15,408
New +$140K ﹤0.01% 484

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Westwood Holdings Group's ABCL Position: Q2 2023 in Review

Westwood Holdings Group sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 15,408 shares — an estimated $116K sold.

Westwood Holdings Group first reported a position in ABCL in Q1 2023 and held it in 1 quarter. The position peaked at $116K in Q1 2023. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Westwood Holdings Group reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Westwood Holdings Group sold 15,408 AbCellera Biologics shares in Q2 2023, an estimated $116K.
  • Westwood Holdings Group first reported a position in AbCellera Biologics in Q1 2023 and held it in 1 quarter.
  • Westwood Holdings Group's AbCellera Biologics position peaked at $116K in Q1 2023.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Westwood Holdings Group's 13F filing for Q2 2023, filed 11 Aug 2023.